Gilead Sciences EBIT

The latest EBIT for GILD is $-1.7B as of June 2026. That compares with $8.2B in the prior-year period — down 120.4% year over year. That is below the Healthcare sector average of $22B. Investors often review this figure alongside Gilead Sciences's historical trend and sector peers before judging valuation or financial health.

Over the past year, GILD's EBIT moved from $8.2B to $-1.7B — a 120.4% year-over-year decrease. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Gilead Sciences's operating scale or balance-sheet position.

Against Healthcare companies, GILD currently prints $-1.7B for EBIT, while the sector average sits near $22B. That is roughly 107.5% below the sector mean. Large gaps often invite a closer look at Gilead Sciences's growth, margins, and balance sheet.

A EBIT figure of $-1.7B for GILD is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. The Healthcare average is about $22B. Explore the charts below for those layers of context.

After noting GILD's EBIT ($-1.7B), review year-over-year change from $8.2B, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.